Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Executive Summary

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Advertisement

Related Content

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room
J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges
'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS
ANI eyes more deals to follow WellSpring
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition
Aimmune Accelerates Commercial Planning For Peanut Allergy Drug
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Immune-Focused Discovery Firm Alpine Goes Public With Nivalis Merger

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124498

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel